<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104767</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000415733</org_study_id>
    <secondary_id>UCLA-0407028-01</secondary_id>
    <nct_id>NCT00104767</nct_id>
    <nct_alias>NCT00744783</nct_alias>
  </id_info>
  <brief_title>Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. It may also stimulate the immune system in different ways and stop&#xD;
      tumor cells from growing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib in&#xD;
      treating patients with stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the optimal biologic dose (OBD) of celecoxib that is necessary to decrease&#xD;
           peripheral blood lymphocyte CD4+ and CD25+ T-lymphocyte regulatory cells in patients&#xD;
           with stage IIIB or IV non-small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the OBD of this drug that is necessary to decrease peripheral blood lymphocyte&#xD;
           FOXP3 levels in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, dose-escalation study.&#xD;
&#xD;
      Patients receive oral celecoxib twice daily on days 1-7 in the absence of unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3 patients receive escalating doses of celecoxib until the optimal biologic dose&#xD;
      (OBD) is determined. The OBD is defined as the lowest dose that results in the maximum&#xD;
      decrease in peripheral blood lymphocyte CD4+ and CD25+ T-lymphocyte regulatory cells and&#xD;
      FOXP3 levels where no dose-limiting toxicity occurs. An additional 15 patients are treated at&#xD;
      the OBD.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal biologic dose (OBD) necessary to decrease peripheral blood lymphocyte (PBL) CD4+ and CD25+ T-lymphocyte regulatory cells at 1 week</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OBD necessary to decrease PBL FOXP3 levels at 1 week</measure>
    <time_frame>7 dayd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function of CD4+ and CD25+ T-regulatory cells at 1 week</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of cyclooxygenase-2 (COX-2) dependent gene expression before and after treatment at 1 week</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <arm_group_label>celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  Stage IIIB or IV disease&#xD;
&#xD;
          -  Radiographically measurable disease&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Renal: Creatinine â‰¤ 2 mg/dL&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent&#xD;
             corticosteroids, including chronic corticosteroids, except for medically-indicated&#xD;
             topical steroids&#xD;
&#xD;
          -  Radiotherapy: More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since other prior anticancer therapy&#xD;
&#xD;
          -  More than 4 weeks since prior non-cytotoxic investigational agents&#xD;
&#xD;
          -  At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  comorbid disease, psychiatric condition, chronic medical condition, or laboratory&#xD;
             abnormality that would preclude study treatment or compliance with study requirements&#xD;
&#xD;
          -  hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study&#xD;
             reagent&#xD;
&#xD;
          -  history of gastrointestinal ulceration, bleeding, or perforation&#xD;
&#xD;
          -  other concurrent cyclooxygenase-2 or -3 inhibitors&#xD;
&#xD;
          -  other concurrent NSAIDs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Garon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

